| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2012.45.0866 |
| P698 | PubMed publication ID | 23530110 |
| P50 | author | Gianluca Gaidano | Q30303486 |
| Stefano Sacchi | Q39945256 | ||
| Luca Arcaini | Q43138347 | ||
| Francesco Merli | Q55602098 | ||
| Stefano Luminari | Q56826847 | ||
| Umberto Vitolo | Q56998074 | ||
| Massimo Federico | Q57031724 | ||
| Massimo Federico | Q57417821 | ||
| P2093 | author name string | Caterina Stelitano | |
| Alessandro Pulsoni | |||
| Vito Franco | |||
| Francesco Di Raimondo | |||
| Luigi Rigacci | |||
| Maura Brugiatelli | |||
| Angelo Michele Carella | |||
| Francesco Angrilli | |||
| Luigi Marcheselli | |||
| Sara Galimberti | |||
| Alessandra Tucci | |||
| Matteo Dell'olio | |||
| Alessandra Dondi | |||
| P433 | issue | 12 | |
| P921 | main subject | follicular lymphoma | Q123251 |
| P304 | page(s) | 1506-1513 | |
| P577 | publication date | 2013-03-25 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi | |
| P478 | volume | 31 |
| Q26776480 | 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr |
| Q33424956 | A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma |
| Q38777460 | Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma. |
| Q24201306 | Anthracycline-containing regimens for treatment of follicular lymphoma in adults |
| Q64906476 | BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA. |
| Q94445994 | Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information |
| Q50058219 | Bayesian hierarchical methods for meta-analysis combining randomized-controlled and single-arm studies. |
| Q64115851 | CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products |
| Q90066133 | Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis |
| Q88257828 | Chemotherapy free treatment of indolent lymphoma |
| Q45252214 | Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study |
| Q52709256 | Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. |
| Q26775837 | Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma |
| Q60019713 | Current challenges in the management of follicular lymphoma |
| Q38345585 | Current therapeutic strategies and new treatment paradigms for follicular lymphoma |
| Q91807399 | Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens |
| Q50220913 | Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era. |
| Q36934350 | Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study |
| Q38676712 | Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. |
| Q35080079 | FDG PET-CT in follicular lymphoma: a case-based evidence review |
| Q33642244 | FDG-PET Scan: a new Paradigm for Follicular Lymphoma Management |
| Q56968723 | Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients |
| Q37231130 | Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy |
| Q92185611 | Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs |
| Q90206157 | Follicular Lymphoma: Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up |
| Q37577856 | Follicular Lymphoma: The Management of Elderly Patient. |
| Q40921950 | Follicular lymphoma |
| Q92348038 | Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade |
| Q39027770 | Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy? |
| Q40063998 | High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study |
| Q34463426 | Hodgkin disease-an ever-evolving therapy |
| Q92103346 | How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation |
| Q38191811 | How we manage follicular lymphoma |
| Q41008736 | Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy. |
| Q52720428 | Impact of Anthracyclines on Diabetes Mellitus Development in B-Cell Lymphoma Patients: A Nationwide Population-based Study. |
| Q33664022 | Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry |
| Q33701036 | In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL). |
| Q37037432 | Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma |
| Q38781996 | Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma |
| Q57165211 | Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study |
| Q42388537 | Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas |
| Q38157345 | Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines |
| Q58801965 | Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group |
| Q42696218 | Metabolic Tumor Volume in Lymphoma: Hype or Hope? |
| Q58565576 | Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial |
| Q37613316 | Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. |
| Q39327223 | Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. |
| Q42427611 | Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi |
| Q97675315 | Precision Medicine In Follicular Lymphoma. Focus On Predictive Biomarkers |
| Q92631610 | Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma |
| Q38794103 | Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies |
| Q38728054 | Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group. |
| Q36448074 | Radiotherapy as an effective treatment modality for follicular lymphoma: a single institution experience |
| Q34663603 | Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study |
| Q64086572 | Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma |
| Q39063872 | Recommendations for Clinical Trial Development in Follicular Lymphoma |
| Q48280234 | Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome |
| Q48619267 | Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. |
| Q46675870 | Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience |
| Q36400279 | SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma. |
| Q33418964 | Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial |
| Q28073262 | Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How |
| Q33565265 | The clinical development of obinutuzumab for the treatment of follicular lymphoma |
| Q35236063 | The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. |
| Q38124009 | The optimal management of follicular lymphoma: an evolving field |
| Q95428618 | Treatment for patients with indolent and mantle cell lymphoma |
| Q50710717 | Unmet needs in the first-line treatment of follicular lymphoma. |
Search more.